Venetoclax Treatment: Dosage, Side Effects, and Uses Explained

Summary of Venetoclax Treatment

Venetoclax is a prescription medication used to treat specific blood cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It works by targeting and blocking a protein that helps cancer cells survive. Venetoclax is typically taken as an oral tablet, with the dosage varying depending on the condition being treated. Always consult your healthcare provider before starting or adjusting your dose.

Names of Venetoclax Medication

US Brand Name: Venclexta

Generic Name: Venetoclax

The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. The generic name is listed in parentheses.

Pharmacologic Category of Venetoclax

BCL-2 Inhibitor

Venetoclax Dosage

Venetoclax is used to treat various blood cancers, and the dosing schedule depends on the specific condition being treated. Always follow your healthcare provider’s instructions and consult them before making any changes to your dose. You can also schedule a telemedicine appointment for personalized guidance.

Venetoclax for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Initial Dose: 20 mg orally once daily for 7 days

Titration: Gradually increase the dose over 5 weeks to a final dose of 400 mg once daily

Duration: Continue until disease progression or unacceptable toxicity

Venetoclax for Acute Myeloid Leukemia (AML)

Initial Dose: 100 mg orally once daily

Titration: May be increased to 400 mg daily depending on response and tolerability

Duration: Varies based on response and tolerance

Venetoclax for Non-Hodgkin Lymphoma (NHL) and Mantle Cell Lymphoma (MCL)

Initial Dose: 20 mg orally once daily for 7 days

Titration: Gradually increase to 400 mg once daily over 5 weeks

Duration: Continue until disease progression or unacceptable toxicity

Venetoclax for Acute Lymphoblastic Leukemia (ALL) and Hairy Cell Leukemia

Initial Dose: 100 mg orally once daily

Titration: May be increased to 400 mg daily based on response

Duration: Depends on individual response

Venetoclax for Multiple Myeloma and Waldenström Macroglobulinemia

Initial Dose: 100 mg orally once daily

Titration: May be increased to 400 mg daily depending on response

Duration: Continue until disease progression or unacceptable toxicity

Venetoclax for Chronic Myeloid Leukemia (CML)

Initial Dose: 100 mg orally once daily

Titration: May be increased to 400 mg daily based on response

Duration: Varies based on response and tolerance

Venetoclax Dosage Forms and Strengths

Tablets: 10 mg, 50 mg, 100 mg

Venetoclax Administration Instructions

Take Venetoclax with food and water to reduce the risk of stomach upset. Swallow the tablets whole; do not crush, chew, or break them. Follow the dosing schedule provided by your healthcare provider. If you miss a dose, take it as soon as you remember, but if it’s almost time for your next dose, skip the missed one. Do not take two doses at the same time. Always consult your healthcare provider for specific instructions.

Venetoclax Side Effects and Adverse Reactions

Like all medications, Venetoclax can cause side effects. Some are common, while others are rare but more serious. If you experience any side effects, contact your healthcare provider immediately. You can also schedule a telemedicine appointment for further assistance.

Common Venetoclax Side Effects

Nausea: Feeling nauseous is common and can often be managed with anti-nausea medications.

Diarrhea: Loose stools are common but can usually be controlled with over-the-counter medications.

Fatigue: Feeling unusually tired or weak is common, especially during the first few weeks of treatment.

Less Common but Serious Venetoclax Side Effects

Tumor Lysis Syndrome (TLS): A serious condition that occurs when cancer cells break down rapidly, releasing substances into the blood that can cause kidney damage. Your healthcare provider will monitor you closely for this.

Low Blood Cell Counts: Venetoclax can cause a decrease in white blood cells, red blood cells, and platelets, increasing the risk of infections, anemia, or bleeding.

Infections: Venetoclax can weaken your immune system, making you more susceptible to infections. Contact your provider if you experience fever, chills, or other signs of infection.

Venetoclax Contraindications

A contraindication is a specific situation where a medication should not be used due to potential harm. Below are the contraindications for Venetoclax:

Severe liver impairment: Venetoclax is processed by the liver, and if the liver is not functioning properly, the medication may not be metabolized correctly, leading to toxic levels in the body.

Hypersensitivity to Venetoclax: If you have had an allergic reaction to Venetoclax or any of its components, taking the medication again could result in severe allergic reactions, including anaphylaxis.

Concomitant use with strong CYP3A inhibitors: Medications that strongly inhibit the CYP3A enzyme (such as ketoconazole) can increase Venetoclax levels in the blood, leading to potentially dangerous side effects like tumor lysis syndrome.

If you have any of these conditions, it is important to discuss them with your healthcare provider. Our telemedicine team is available to help you determine if Venetoclax is right for you.

Drug to Drug Interactions with Venetoclax

Venetoclax can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. Below are some medications that may interact with Venetoclax:

Ketoconazole (Nizoral): A strong CYP3A inhibitor that can elevate Venetoclax levels in the blood, increasing the risk of toxicity.

Rifampin (Rifadin): A strong CYP3A inducer that can lower Venetoclax levels, potentially reducing its effectiveness.

Phenytoin (Dilantin): Another CYP3A inducer that may decrease Venetoclax’s effectiveness.

Clarithromycin (Biaxin): A strong CYP3A inhibitor that can raise Venetoclax levels, heightening the risk of side effects.

Warfarin (Coumadin): Venetoclax may enhance the effects of warfarin, increasing the risk of bleeding.

Always inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Our telemedicine providers can review your medication list to ensure Venetoclax is safe for you.

Venetoclax in Pregnancy: Is It Safe?

No, Venetoclax is not considered safe during pregnancy. It may cause harm to an unborn baby, including birth defects or miscarriage. Women of childbearing age should use effective contraception during treatment and for at least 30 days after the last dose of Venetoclax. If you are pregnant or planning to become pregnant, discuss this with your healthcare provider. You can schedule a telemedicine consultation with one of our providers to explore safer alternatives during pregnancy.

Venetoclax While Breastfeeding: What You Need to Know

No, Venetoclax is not recommended while breastfeeding. It is unclear whether Venetoclax passes into breast milk, but due to the potential for serious side effects in a nursing infant, breastfeeding should be avoided during treatment and for at least one week after the last dose. If you are breastfeeding or planning to breastfeed, talk to your healthcare provider about your options. Our telemedicine team is available to discuss alternative treatments or feeding options.

Estimated Cost of Venetoclax Treatment

The cost of Venetoclax can vary depending on your location and pharmacy. Without insurance, the estimated cost for a 30-day supply of Venetoclax (100 mg tablets) ranges from $12,000 to $14,000 with a GoodRx coupon. Check with your pharmacy for the most accurate pricing, and consider exploring patient assistance programs or insurance coverage options.

Possible Alternatives to Venetoclax

If Venetoclax is not suitable for you or if you’re seeking alternative treatments, other options are available depending on your condition. Always consult your healthcare provider before making changes to your treatment plan. Our telemedicine providers can help you explore these alternatives.

Chronic lymphocytic leukemia (CLL): Alternatives include targeted therapies like Ibrutinib (Imbruvica), chemotherapy, or monoclonal antibodies such as Rituximab (Rituxan).

Acute myeloid leukemia (AML): Treatment options may include chemotherapy, stem cell transplantation, or newer targeted therapies like Midostaurin (Rydapt).

Small lymphocytic lymphoma (SLL): Similar to CLL, treatment options include Ibrutinib (Imbruvica) or chemotherapy with monoclonal antibodies.

Non-Hodgkin lymphoma: Treatments may include chemotherapy, radiation therapy, or targeted therapies such as Rituximab (Rituxan).

Mantle cell lymphoma: Alternatives include Ibrutinib (Imbruvica), chemotherapy, or stem cell transplantation.

Acute lymphoblastic leukemia (ALL): Treatment may involve chemotherapy, targeted therapies, or stem cell transplantation.

Hairy cell leukemia: Alternatives include chemotherapy with Cladribine or Pentostatin, or targeted therapies like Rituximab (Rituxan).

Multiple myeloma: Treatment options include chemotherapy, immunomodulatory drugs like Lenalidomide (Revlimid), or proteasome inhibitors like Bortezomib (Velcade).

Waldenström macroglobulinemia: Alternatives include Rituximab (Rituxan), chemotherapy, or targeted therapies like Ibrutinib (Imbruvica).

Chronic myeloid leukemia (CML): Targeted therapies like Imatinib (Gleevec) or Dasatinib (Sprycel) are commonly used as alternatives.

Recent Updates on Venetoclax Research

Recent research on Venetoclax has focused on expanding its use in various blood cancers. Studies are exploring combinations of Venetoclax with other therapies to improve outcomes in patients with difficult-to-treat cancers. For example, ongoing clinical trials are investigating Venetoclax with hypomethylating agents for treating acute myeloid leukemia (AML) in elderly patients who cannot tolerate intensive chemotherapy. Additionally, researchers are studying Venetoclax in combination with other targeted therapies for chronic lymphocytic leukemia (CLL) to potentially reduce treatment duration while maintaining long-term remission.

These studies are promising, but it is important to discuss any new treatment options with your healthcare provider. If you’re interested in learning more about Venetoclax or participating in a clinical trial, our telemedicine providers are available to guide you through your options.

James Kingsley

Learn More